NIKKEI 225
26,447.79-196.92(-0.74%)HANG SENG
26,577.32-317.36(-1.18%)CRUDE OIL
44.87-0.66(-1.45%)
CytRx Corporation (CYTR)
| Previous close | 0.7350 |
| Open | 0.7450 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 1000 |
| Day's range | 0.7000 - 0.7500 |
| 52-week range | 0.2300 - 0.8500 |
| Volume | 39,042 |
| Avg. volume | 44,498 |
| Market cap | 26.266M |
| Beta (5Y monthly) | 1.72 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2440 |
| Earnings date | 16 Nov 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
CytRx Comments on Quarterly Results and Recent Strategic Progress
CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the third quarter ended September 30, 2020. In addition, CytRx highlighted recent steps to support Centurion Biopharma’s progress as well as external developments pertaining to its agreements with ImmunityBio, Inc. ("ImmunityBio") and Orphazyme A/S ("Orphazyme"). The Company’s 10-Q was filed on November 13, 2020.
- Business Wire
CytRx Highlights Orphazyme’s Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C
CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that Orphazyme A/S (ORPHA) (NASDAQ:ORPH) ("Orphazyme") has submitted a Marketing Authorisation Application ("MAA") to the European Medicines Agency ("EMA") for arimoclomol in the treatment of Niemann-Pick disease Type C ("NPC"). CytRx has an agreement with Orphazyme that can yield potential milestone payments and future royalties paid on sales of arimoclomol.
- Business Wire
CytRx Highlights Orphazyme’s Acceleration of Pre-Launch Activities for Arimoclomol
CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that Orphazyme A/S (ORPHA.CO) (NASDAQ:ORPH) ("Orphazyme") has announced new plans to accelerate commercial and other pre-launch activities during the fourth quarter of 2020 in preparation for potential approval of arimoclomol in Niemann-Pick disease Type C ("NPC"), which is currently under Priority Review by the U.S. Food and Drug Administration ("FDA") with a target action date of March 17, 2021. CytRx has an agreement with Orphazyme that can yield potential milestone payments and future royalties paid on sales of arimoclomol.
